@Article{info:doi/10.2196/24424,
author="Coughlin, Lara N
and Nahum-Shani, Inbal
and Philyaw-Kotov, Meredith L
and Bonar, Erin E
and Rabbi, Mashfiqui
and Klasnja, Predrag
and Murphy, Susan
and Walton, Maureen A",
title="Developing an Adaptive Mobile Intervention to Address Risky Substance Use Among Adolescents and Emerging Adults: Usability Study",
journal="JMIR Mhealth Uhealth",
year="2021",
month="Jan",
day="15",
volume="9",
number="1",
pages="e24424",
keywords="mHealth; adolescents; young adults; just-in-time adaptive intervention; alcohol misuse; cannabis; mobile phone",
abstract="Background: Substance use among adolescents and emerging adults continues to be an important public health problem associated with morbidity and mortality. Mobile health (mHealth) provides a promising approach to deliver just-in-time adaptive interventions (JITAIs) to prevent escalation of use and substance use--related consequences. Objective: This pilot study aims to describe the iterative development and initial feasibility and acceptability testing of an mHealth smartphone app, called MiSARA, designed to reduce escalation in substance use. Methods: We used social media advertisements to recruit youth (n=39; aged 16-24 years, who screened positive for past-month binge drinking or recreational cannabis use) with a waiver of parental consent. Participants used the MiSARA app for 30 days, with feasibility and acceptability data reported at a 1-month follow-up. We present descriptive data regarding behavior changes over time. Results: The results show that most participants (31/39, 79{\%}) somewhat liked the app at least, with most (29/39, 74{\%}) rating MiSARA as 3 or more stars (out of 5). Almost all participants were comfortable with self-reporting sensitive information within the app (36/39, 92{\%}); however, most participants also desired more interactivity (27/39, 69{\%}). In addition, participants' substance use declined over time, and those reporting using the app more often reported less substance use at the 1-month follow-up than those who reported using the app less often. Conclusions: The findings suggest that the MiSARA app is a promising platform for JITAI delivery, with future trials needed to optimize the timing and dose of messages and determine efficacy. ",
issn="2291-5222",
doi="10.2196/24424",
url="http://mhealth.jmir.org/2021/1/e24424/",
url="https://doi.org/10.2196/24424",
url="http://www.ncbi.nlm.nih.gov/pubmed/33448931"
}